Wave Life Sciences Ltd (NASDAQ:WVE) Q4 2022 Earnings Conference Call March 22, 2023 8:30 AM ET

Company Participants

Paul Bolno - President & Chief Executive Officer

Anne-Marie Li-Kwai-Cheung - Chief Development Officer

Kyle Moran - Chief Financial Officer

Conference Call Participants

Mike Linden - Mizuho

Joon Lee - Truist Securities

Julian Pino - Stifel

Operator

Good morning, and welcome to the Wave Life Sciences Fourth Quarter and Full Year 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode. As a reminder, this call is being recorded and webcast.

I'll now turn the call over to [Kia Telepore] (ph), Wave's IR Consultant. Please go ahead.

Unidentified Company Representative

Thank you, operator. Good morning, and thank you for joining us today to discuss our recent business progress and review Wave's fourth quarter and full year 2022 financial results. Joining me today are Dr. Paul Bolno, President and Chief Executive Officer; Anne-Marie Li-Kwai-Cheung, Chief Development Officer; Kyle Moran, Chief Financial Officer; and Dr. Chandra Vargeese, Chief Technology Officer.

The press release issued this morning and the slide presentation to accompany this webcast are available in the Investors Section of our website at www.wavelifesciences.com.

Before we begin, I would like to remind you that discussions during this conference call will include forward-looking statements. These statements are subject to several risks and uncertainties that could cause our actual results to differ materially from those described in these forward-looking statements. The factors that could cause actual results to differ are discussed in the press release issued today, and in our SEC filings. We undertake no obligation to update or revise any forward-looking statements for any reason.

Now, I'd like to turn the call over to Paul.

Paul Bolno

Thanks, Kia. Good morning and thank you all for joining us. I'm excited to begin today's call with a review of recent business highlights and how they position Wave in 2023 and beyond. I'll then turn the call over to Anne-Marie to discuss our clinical development update with a focus on DMD. Kyle will discuss our financial results and I will end with a summary of upcoming catalysts expected in 2023. We'll then proceed to the Q&A portion of the call where Chandra will also be available.

At Wave, we believe the power of our PRISM platform and the potential of our current and future pipeline has positioned us to become the leading RNA medicines company. PRISM is the most versatile discovery and drug development platform in the industry. It offers three distinct RNA targeting modalities: editing, slicing and silencing, so that we can design built for purpose molecules that optimally address disease biology. Our platform reflects nearly a decade of investment in proprietary chemistry which are disrupting the existing dogma of oligonucleotides, and are opening up new capabilities. Our chemistry advancements have also enabled us to push into new areas of disease biology that were not accessible or were inadequately addressed with other modalities. And we continue to build a pipeline of innovative first or best-in-class candidates.